Last edited by Gardakazahn
Thursday, April 23, 2020 | History

2 edition of Plasminogen and urokinase determination based on the lysis time method. found in the catalog.

Plasminogen and urokinase determination based on the lysis time method.

Walter Berg

Plasminogen and urokinase determination based on the lysis time method.

Purification of the substrates. Kinetic and methodological studies.

by Walter Berg

  • 123 Want to read
  • 11 Currently reading

Published by Almqvist & Wiksell bokhandel (distr.)] in [Stockholm .
Written in English

    Subjects:
  • Plasminogen.,
  • Plasminokinase.,
  • Blood -- Analysis.,
  • Blood -- analysis.,
  • Fibrinolytic Agents -- analysis.,
  • Plasminogen -- analysis.

  • Edition Notes

    Bibliography: p. 43-45.

    SeriesActa medica Scandinavica. Supplementum, 478
    Classifications
    LC ClassificationsQP93.5
    The Physical Object
    Pagination45 p.
    Number of Pages45
    ID Numbers
    Open LibraryOL5260350M
    LC Control Number75360152

      Extracellular proteases such as plasminogen activators (PAs) and matrix metalloproteinases modulate cell-cell and cell-matrix interactions. Components of the PA/plasmin system have been shown to be increased in areas of inflammation, and have been suggested to play a role in inflammatory neurologic disorders such as epilepsy, stroke, brain trauma, Cited by:   Preclinical evaluation of a urokinase plasminogen activator receptor-targeted nanoprobe in rhesus monkeys Yushu Chen,1 Li Gong,2 Ning Gao,3 Jichun Liao,1 Jiayu Sun,1 Yuqing Wang,1 Lei Wang,1 Pengjin Zhu,1 Qing Fan,1 Yongqiang Andrew Wang,4 Wen Zeng,2 Hui Mao,3 Lily Yang,5 Fabao Gao11Molecular Imaging Center, Department of Radiology, . Function: Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. Gene References into Functions: The combination of decoy receptor 3, soluble urokinase type plasminogen activator receptor, and procalcitonin improved the sensitivity and specificity of diagnosis of sepsis, suggesting that use of the combination of three indexes enhanced the Abbreviation: uPA. Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase ε/PRSS22 Shinsuke Yasuda, Nasa Morokawa, G. William Wong, Andrea Rossi, Mallur S. Madhusudhan, Andrej Šali, Yuko S. Askew, Roberto Adachi, Gary A. Silverman, Steven A. Krilis, Richard L. StevensCited by:


Share this book
You might also like
Federally chartered corporation

Federally chartered corporation

Japanese pâtisserie

Japanese pâtisserie

Management and the social sciences

Management and the social sciences

60 years

60 years

Hermes

Hermes

Naturalization amendments of 1987

Naturalization amendments of 1987

Six degrees of separation

Six degrees of separation

Gloeocystidiellaceae (Basidiomycota, Hericiales) of North America

Gloeocystidiellaceae (Basidiomycota, Hericiales) of North America

AutoCAD Release 14 Update Student Guide - French Canadian

AutoCAD Release 14 Update Student Guide - French Canadian

Facsimiles of bibliographical format

Facsimiles of bibliographical format

The Quaternary-Paleozoic geology of the Hamilton-London-Chatham area, southern Ontario. Edited by Edward V. Sado

The Quaternary-Paleozoic geology of the Hamilton-London-Chatham area, southern Ontario. Edited by Edward V. Sado

Plasminogen and urokinase determination based on the lysis time method. by Walter Berg Download PDF EPUB FB2

Plasminogen and urokinase determination based on the lysis time method. Purification of the substrates. Kinetic and methodological studies.

Prabhjit K. Grewal, in Methods in Enzymology, Plasminogen activity assay. Urokinase activated plasminogen is measured by chromogenic substrate specific for plasmin and urokinase activated plasminogen in diluted citrated plasma samples using well plates read by a Versa Max microplate reader (Molecular Devices, CA).

Sixty microliters of plasma sample dilution. Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many s: PLAU, uPA, Urokinase-type plasminogen.

Author(s): Berg,Walter Title(s): Plasminogen and urokinase determination based on the lysis time method. Purification of the substrates, kinetic and methodological studies. Country of Publication: Sweden Publisher: Göteborg, This sensitive assay can be used for the determination of tissue plasminogen activator in the plasma during thrombolytic therapy, and may be helpful for designing a standard dosage of tissue plasminogen activator.

Determination of tissue plasminogen activator by the enzyme-immunoassay method discriminates non-UK type plasminogen activator from by: the activation of ptasminogen by pro-urokinase is due to neutralization by fibrin of the competitive inhibition exerted by plasma and not to fibrin-enhanced activa- tion of plasminogen.

Urokinase is a trypsin-like serine protease composed of two polypeptide chains (Mr 20, ) connected by a single disulfide bridge.

Urokinase was associated with an intermediate rate of lysis but appeared to be the agent with the greatest degree of fibrinolytic specificity (p = vs streptokinase, p = vs rt-PA). Although rt-PA was associated with improved efficacy early in the perfusions, the differences between rt-PA and urokinase dissipated after 30 by: The determination of total fibrinolytic activity of ejaculates was realized by fibrin plate method.

For the same seminal samples, tissue plasminogen activator (t-PA), urinary plasminogen activator. Plasminogen activators are serine proteases that catalyze the activation of plasmin via proteolytic cleavage of its zymogen form n is an important factor in fibrinolysis, the breakdown of fibrin polymers formed during blood clotting.

There are two main plasminogen activators: urokinase (uPA) and tissue plasminogen activator (tPA). Tissue plasminogen. Isolation and characterization of urokinase from human plasma Article (PDF Available) in Journal of Biological Chemistry (6) April with 58 Reads How we measure 'reads'. The activation of human plasminogen by urokinase has been examined by sodium dodecyl sulfate gel electrophoresis and by amino acid sequence analysis.

Plasminogen, purified from human plasma by afbnity chromatography, was found to have a. Jones, A. J., and Meunier, A. M.,A precise and rapid microtitre plate clot lysis assay: Methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis, Thromb Haemostasis –Cited by: U, 0 c E n 1= z-o0-J 0 w 80 60 40 20 IL I I II HEMOLYZED RED CELLS ADDED, ml FIGURE 1 Effect of increasing amounts of red cells on plasma euglobulin lysis time.

Varying amounts of washed, hemolyzed red cells from one subject were added to a constant amountof his plasma ( ml), and the euglobulin precipitated from this mixture was. Plasma plasminogen levels can be measured directly or indirectly. Indirect methods are based on the activation of the inactive plasminogen by streptokinase (SK) or urokinase (UK) to active plasmin which, being a proteolytic enzyme, can be assayed using.

ABSTRACT Lysis of fibrin in tissue culture has been shown to be due to plasminogen activator identified im-munologically as urokinase. The present study examines fibrinolytic events in culture, particularly mechanisms leading to increased urokinase levels and accelerated fibrinolysis. Deposition of fibrin on cells in culture was followed.

Tests of fibrinolytic activity, such as fibrinogen concentration, FDP/fdp titer, reptilase clotting time, {18} {27} and/or whole blood euglobulin lysis time (recommended 3 to 4 hours following initiation of intravenous therapy for indications other than acute coronary arterial thrombosis; these tests may be repeated every 12 hours for the.

Tissue plasminogen activator (tPA, tissue-type plasminogen activator) is a serine protease found on endothelial cells (cells that line the blood vessels) involved in the breakdown of blood clots (fibrinolysis). tPA enzyme catalyzes the conversion of plasminogen to plasmin.

tPA can used in embolic or thrombotic stroke research. tPA may be manufactured using recombinant. Urokinase-type Plasminogen Activator; Synonym: uPA; find Sigma-Aldrich-CC MSDS, related peer-reviewed papers, technical documents, similar products & more at Sigma-Aldrich.

Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally identified as a blood-derived endogenous fast-acting inhibitor of uPA.

At concentrations found in tumor tissue, however, both PAI-1 and uPA Cited by: (data not shown). FIGURE 2 presents the time- and urokinase concentration- dependence of the reaction. Urokinase activity is not reproducibly linear beyond 45 min, even in the absence of substrate depletion.

A direct comparison was made to a sensitive [1Z51]fibrin-lysis assay usingCited by:   The urokinase plasminogen activator and its inhibitor are proteins found on the outside of breast cancer tumor cells that help the cancer grow and spread.

Higher levels of these proteins have been linked to worse outcomes. Testing for these two proteins is done on breast cancer tissue removed during biopsy or surgery.

plasminogen activator in tissue are the potassium thiocyanate extraction technique' and the his-tochemical fibrin slide method first described by Todd2 and modified by Pandolfi et al.3 The latter methodhasbeen used most commonlyto study the relation between disease and tissue plasminogen activator but despite various scoring systems remains Cited by: 1.

Varying volumes of Plasminogen (not exceeding ml) may be added to the test reaction mix. Bring the volume of plasminogen up to ml with deionized water.

For each test a blank must be run containing the same amount of plasminogen. This assay is based on the cited references. Where Sigma Product or Stock numbers are specified. This report describes the criteria for a specific method for determination of plasminogen (enzymatic; procedure) in human plasma.

The criteria are restricted to glu-plasminogen, but other forms of plasminogen such as lys- and mini-plasminogen are not expected to be found in human plasma. However, in any case when these forms are to be analysed aFile Size: 1MB. urokinase-type plasminogen activator receptor ELISA Kits The ELISA (enzyme-linked immunosorbent assay) is a widely used application for detecting and quantifying proteins and antigens from various samples.

Human Retinal Pigment Epithelial Lysis of Extracellular Matrix lularly The promotor of the gelatinase A gene lacks the TPA (tetradecanoylphorbolacetate) responsive ele-ment and the transactivator sequences, AP-1 and PEA The promotor also lacks a. Urokinase plasminogen activator (uPA) is a serine protease that catalyzes the conversion of plasminogen to plasmin.

However, the specificity of the inhibitory reaction with tPA and uPA was notably higher than that for the substrate reaction catalyzed by elastase. pH dependences of k(lim) and K() obtained for tPA revealed an additional.

PLAU - Plasminogen Activator, Urokinase. Looking for abbreviations of PLAU. It is Plasminogen Activator, Urokinase. Plasminogen Activator, Urokinase listed as PLAU.

Plasminogen Activator, Urokinase; Plasminogen Activators in Plasma and Urine. Plasminogen (MW: 92 Kda) is the zymogen form of plasmin (83 KDa). The activation of plasminogen is accomplished by t-PA, urokinase or streptokinase.

It is not the purpose of this text to describe the mechanisms of activation of plasminogen and its inhibition, but it is important to underline that they can affect the reaction of the active.

Radioactive Methanol Method Discussion Assays of the Plasminogen Activator in Tissues Principles Reagents and Materials Preparation of Fibrin Plates Isolation of Tissue Activator Assay on Fibrin Plates The Clot Lysis Time Method Assay Methods for Individual Fibrinolytic Components — Urokinase and Streptokinase Introduction Urokinase AssayBook Edition: 1.

Learn plasminogen activator with free interactive flashcards. Choose from 43 different sets of plasminogen activator flashcards on Quizlet.

The urokinase plasminogen activator receptor is highly expressed and its gene is amplified in about 50% of pancreatic ductal adenocarcinomas; this last feature is associated with worse prognosis.

It is unknown whether the level of its soluble form (suPAR) in urine may be a diagnostic-prognostic marker in these patients. The urinary level of suPAR was measured in Cited by: T1 - The urokinase plasminogen activator receptor as a target for cancer therapy.

AU - D'Alessio, Silvia. AU - Blasi, Francesco. PY - Y1 - N2 - Proteolytic processes are necessary for normal physiological functions in the body, including normal blood vessel maintenance, clot formation and dissolution, bone remodeling, and by: 1.

A˚6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I triali Anna Berkenblita,i,*, Ursula A. Matulonisb,i, Joan F. Kroenerc, Bruce J. Dezubea,i, Gil N. Lamd, Luceli C. Cuasaye, Nils Bru¨nnerf, Terence R.

Jonesg, Michael H. Silvermanh, Michael A. Goldj aDivision of Hematology and Oncology, Department of. Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein (molecular weight, 47 kDa) that is synthesized in endothelial cells, hepatocytes, and adipocytes.

It can also be released from activated platelets. PAI-1 circulates in the blood in both its active form (half-life of 30 minutes) and its latent form (half-life of 2 hours). Urokinase plasminogen activator (uPA) has an amino-terminal fragment (ATF) which binds to GPI-anchored uPA receptor, and a C-terminal protease domain.

This is the crystal structure of the ATF. Background: u-Plasminogen Activator (uPA)/Urokinase. uPA is a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-ArgValVal-Gly-Gly-Cys in plasminogen to form plasmin (1). uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder.

uPAsr - Urokinase Plasminogen Activator Soluble Receptor. Looking for abbreviations of uPAsr. It is Urokinase Plasminogen Activator Soluble Receptor. Urokinase Plasminogen Activator Soluble Receptor listed as uPAsr. urokinase type plasminogen activator; Urokinase-Like Plasminogen Activator.

Other articles where Tissue plasminogen activator is discussed: fibrinolytic drug: Tissue plasminogen activator (t-PA) stimulates fibrinolysis, and it has several important advantages over streptokinase and urokinase in treating coronary thrombosis.

It binds readily to fibrin and, after intravenous administration, activates only the plasminogen that is bound to the clot; thus.

Plasminogen is converted into active plasmin by a variety of enzymes, including tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). Fibrin is a cofactor for plasminogen activation by tissue plasminogen activator.

PAI-1 is an inhibitor of tissue type plasminogen activators (t-PA) and urokinase type plasminogen activators (u-PA), which convert plasminogen to plasmin, the primary protease responsible for fibrinolysis.

Thus, complete PAI-1 deficiency results in excessive fibrinolysis manifesting as mild to moderate bleeding [Heiman et al ].In thrombolytic therapy, plasminogen activators (PAs) are still the only group of drug approved to induce thrombolysis, and therefore, critical for treatment of arterial thromboembolism, such as stroke, in the acute phase.

Functionalized nanocomposites have attracted great attention in achieving target thrombolysis due to favorable characteristics associated with the size, surface Author: Yunn-Hwa Ma, Chih-Hsin Liu, Yueh Liang, Jyh-Ping Chen, Tony Wu.The Plasminogen Activation System and Cancer 32 Clinical Application of uPA System Research in Breast Cancer Diagnostics and Treatment 33 Quantification Methods for uPA and PAI-1 35 Objectives 37 2 MATERIALS AND METHODS 38 The LightCycler Method 38 Cell Lines 43 Patient Cohorts